GlaxoSmithKline launches Eno digestive antacid in tablet, liquid forms
Used to cure acidity and other gastric issues, Eno was earlier available only in powder form. With the transition into tablet, liquid forms, Eno will now compete with
The European Commission (EC) has approved Merck & Co’s (MSD) Keytruda (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) as a neoadjuvant treatment for muscle-invasive bladder cancer (MIBC).